Study endorses safety of two measles vaccines
The Kaiser Permanente Vaccine Study Center conducted the study to determine the overall safety of the measles-mumps-rubella-varicella (MMRV) vaccine and the same-day measles-mumps-rubella and varicella (MMR + V) vaccines.
The study involved children between the ages of 12 and 23 months. It began on Jan. 2000 and ended June 2012. All of these children received of the above vaccines.
When the analysts compared the two vaccines, they did not find any increased risk of major blood, neurological or immune system health conditions: meningitis/encephalitis, ataxia, arthritis, immune thrombocytopenia purpura, anaphylaxis, Kawasaki disease and acute disseminated encephalomyelitis.
“This study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine,” Nicola P. Klein, M.D., Ph.D., lead author of the study and co-director of the Vaccine Study Center, said. “In fact, there were few or zero events for several outcomes following vaccination. These findings indicate that even if an increased risk for these outcomes exists, the risk is low and rare. This should reassure parents that these outcomes are unlikely after either vaccine.”
Further details are published in Pediatrics.